For upcoming studies, it would be important to identify any potential high-risk subgroups as well as assess whether the elevated risk of NAION is a drug class effect or a specific finding for subcutaneously administered semaglutide. 12.02.24 MDL cases continued to grow in December The GLP-1 MDL continued to grow, bringing the total number of cases in the docket to 1,300
390:1394-1407 [PubMed: 38587233] 319
Recommended Next Reads Build a stronger tracking plan with our best GLP-1 app guide, GLP-1 tracker app overview, semaglutide guide, and tirzepatide guide
This combination of medication support and lifestyle changes gives you the best chance for long-term success
Aim for 2-5 times per week for 30-45 minutes per session
You should immediately seek medical attention if you have: severe vomiting and diarrhea severe pain or tenderness in your belly inability to pass gas or move your bowels jaundice (yellow skin color)